ELAB
Price
$2.17
Change
+$0.02 (+0.93%)
Updated
Jun 6 closing price
Capitalization
2.98M
PRAX
Price
$44.56
Change
+$2.30 (+5.44%)
Updated
Jun 6 closing price
Capitalization
907.64M
73 days until earnings call
Interact to see
Advertisement

ELAB vs PRAX

Header iconELAB vs PRAX Comparison
Open Charts ELAB vs PRAXBanner chart's image
PMGC Holdings
Price$2.17
Change+$0.02 (+0.93%)
Volume$18.78K
Capitalization2.98M
Praxis Precision Medicines
Price$44.56
Change+$2.30 (+5.44%)
Volume$443.61K
Capitalization907.64M
ELAB vs PRAX Comparison Chart
Loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAB vs. PRAX commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a StrongBuy and PRAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ELAB: $2.17 vs. PRAX: $44.56)
Brand notoriety: ELAB and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 3% vs. PRAX: 104%
Market capitalization -- ELAB: $2.98M vs. PRAX: $907.64M
ELAB [@Biotechnology] is valued at $2.98M. PRAX’s [@Biotechnology] market capitalization is $907.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 1 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s).

  • ELAB’s FA Score: 1 green, 4 red.
  • PRAX’s FA Score: 0 green, 5 red.
According to our system of comparison, PRAX is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 4 TA indicator(s) are bullish while PRAX’s TA Score has 6 bullish TA indicator(s).

  • ELAB’s TA Score: 4 bullish, 3 bearish.
  • PRAX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PRAX is a better buy in the short-term than ELAB.

Price Growth

ELAB (@Biotechnology) experienced а +3.83% price change this week, while PRAX (@Biotechnology) price change was +15.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

PRAX is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRAX($908M) has a higher market cap than ELAB($2.99M). PRAX YTD gains are higher at: -42.100 vs. ELAB (-86.463). ELAB has higher annual earnings (EBITDA): -4.75M vs. PRAX (-232.71M). PRAX has more cash in the bank: 328M vs. ELAB (6.43M). ELAB has less debt than PRAX: ELAB (103K) vs PRAX (1.07M). PRAX has higher revenues than ELAB: PRAX (8.12M) vs ELAB (2.45M).
ELABPRAXELAB / PRAX
Capitalization2.99M908M0%
EBITDA-4.75M-232.71M2%
Gain YTD-86.463-42.100205%
P/E RatioN/AN/A-
Revenue2.45M8.12M30%
Total Cash6.43M328M2%
Total Debt103K1.07M10%
TECHNICAL ANALYSIS
Technical Analysis
ELABPRAX
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 19 days ago
86%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGOAX24.72N/A
N/A
Columbia Small Cap Growth A
POVEX30.46N/A
N/A
Putnam International Equity R6
FSGGX16.72N/A
N/A
Fidelity Global ex US Index
FREEX16.98N/A
N/A
Franklin Real Estate Securities A
EAAAX15.58N/A
N/A
Gabelli Entpr Mergers & Acquisitions AAA

ELAB and

Correlation & Price change

A.I.dvisor tells us that ELAB and EPIX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELAB and EPIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
+0.93%
EPIX - ELAB
30%
Poorly correlated
N/A
LXRX - ELAB
25%
Poorly correlated
+6.93%
EDSA - ELAB
22%
Poorly correlated
-6.63%
REGN - ELAB
20%
Poorly correlated
+2.10%
PRAX - ELAB
20%
Poorly correlated
+5.44%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with CDXS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then CDXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
+5.44%
CDXS - PRAX
48%
Loosely correlated
+4.87%
MNMD - PRAX
45%
Loosely correlated
+1.30%
ABCL - PRAX
44%
Loosely correlated
+2.95%
DNLI - PRAX
43%
Loosely correlated
+3.38%
XENE - PRAX
40%
Loosely correlated
+2.96%
More